IGFBP4 Antibody

說明書

中文名稱：

IGFBP4兔多克隆抗體
貨號：

CSB-PA636640
規(guī)格：

￥1100
圖片：
The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using CSB-PA636640(IGFBP4 Antibody) at dilution 1/25, on the right is treated with fusion protein. (Original magnification: ×200)

The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CSB-PA636640(IGFBP4 Antibody) at dilution 1/25, on the right is treated with fusion protein. (Original magnification: ×200)
其他：

產(chǎn)品詳情
產(chǎn)品評價
相關(guān)產(chǎn)品
靶點詳情

產(chǎn)品詳情

Uniprot No.：

P22692
基因名：

IGFBP4
別名：

AI875747 antibody; BP 4 antibody; BP4 antibody; Deb2 antibody; HT29 IGFBP antibody; IBP 4 antibody; IBP-4 antibody; IBP4 antibody; IBP4_HUMAN antibody; IGF binding protein 4 antibody; IGF-binding protein 4 antibody; IGF-BP4 antibody; IGFBP 4 antibody; IGFBP-4 antibody; IGFBP4 antibody; Insulin Like Growth Factor Binding Protein 4 antibody; Insulin-like growth factor-binding protein 4 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human,Mouse,Rat
免疫原：

Fusion protein of Human IGFBP4
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA,IHC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:2000-1:5000
IHC	1:25-1:100

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評價

靶點詳情

功能：

IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors.
基因功能參考文獻：
1. The authors also identified single-nucleotide polymorphisms in NRP2 and IGFBP4 loci that increase and reduce risk of lichen planus in hepatitis C virus-infected patients, respectively. PMID: 28065765
2. the results of this study raise the possibility that human mesenchymal stem cells actions involve a negative-regulatory mechanism that suppresses Treg proliferation by releasing IGFBP-4 PMID: 28724578
3. IGFBP-4 maybe act as a potential negative regulator in the progression of lung cancer through downregulation of COX-2. PMID: 28150906
4. Patients with type 2 Diabetes Mellitus had lower serum concentrations of IGFBP-4 compared to controls. PMID: 28179448
5. Data show that insulin-like growth factor binding protein-4 (IGFBP-4) was significantly elevated in lupus nephritis, particularly those with renal pathology chronicity changes. PMID: 27019456
6. The present study provides the first evidence that apoptosis inhibitor of macrophages binds to IGFBP2, 3 and 4. PMID: 26135353
7. Data show that co-transfection with cDNA encoding stanniocalcin-1 abrogates the proteolytic activity of pregnancy-associated plasma protein-A (PAPP-A) toward IGF-binding protein 4 (IGFBP-4). PMID: 26195635
8. PLasma IGFBP-4 levels are not acutely altered following myocardial infarction treated with heparin and percutaneous coronary intervention. PMID: 25489725
9. High IGFBP-4 fragment levels were associated with increased all-cause and cardiovascular mortality rates in T1D patients with and without diabetic nephropathy. PMID: 26046968
10. Data indicate co-localization of insulin-like growth factor binding proteins IGFBP-4, IGFBP-5 in the syncytiotrophoblast layer of first trimester placental villi as early as 5 weeks of gestational age. PMID: 25475528
11. IGF-1/IGFbp4 signaling regulated the post-developmental adipose tissue expansion. PMID: 24778188
12. Despite the relation of CT-IGFBP4 to a more severe coronary artery disease, CT- and NT-IGFBP4, in contrast to our report based on total PAPP-A, failed to predict any long-term outcomes in patients with stable cardiovascular disease. PMID: 24201068
13. these findings demonstrate an oncogenic property for IBP in promoting the metastatic potential of breast cancer cells. PMID: 23975422
14. PAPP-A and IGFBP-4 gene expression (microarray analysis) was significantly upregulated in IL-1beta- or TNF-alpha-exposed cells. PMID: 24060054
15. IGFBP-4 modulates the efficiency of estrogen-triggered activation of the Akt/PKB signaling pathway which has been associated with growth factor/ ERalpha cross-talks. PMID: 23499909
16. Epigenetic silencing of UCHL1 and IGFBP4 in giant cell tumors may be important for malignant transformation of the cells PMID: 23603559
17. IGFBP-4 was by far the most predominant IGFBP by immunoassay PMID: 23079385
18. role of IGFBP-4 in regulating IGF bioavailability and provide new clues for the prevention and treatment of FGR (Fetal growth restriction). PMID: 22689691
19. IGF1 haplotypes are associated with genetic susceptibility to high myopia in Chinese adults, whereas IGFBP3 and IGFBP4 are unlikely to be important in the genetic predisposition to high myopia PMID: 22332214
20. The resistance of VEGF-stimulated angiogenesis to IGFBP-4 inhibition appears to depend on sustained activation of p38 MAPK as blocking its activity restored the anti-angiogenic effects of IGFBP-4 on VEGF-induced blood vessel growth in vivo PMID: 22134921
21. This study demonistrated that IGFBP4 was significantly decreased in skeletal muscel in patient with amyotrophic lateral sclerosis. PMID: 22246875
22. circulating IGFBP-4 levels are not influenced by secondary hyperparathyroidism in vitamin D deficiency rickets PMID: 21274331
23. This is a first report documenting that IGFBP-4 expression in RCC activates cell growth, metastasis, Wnt/beta-catenin signaling and may be involved in RCC metastasis. PMID: 21207373
24. These findings suggest that the expression of IGFBP-4 in adenocarcinoma cells in vivo is downregulated by epigenetic silencing in association with tumor differentiation, resulting in disruption of the mechanism of IGFBP-4-mediated growth inhibition. PMID: 21166939
25. enterocyte HT-29 cell differentiation correlates with an increase in IGFBP-4 levels PMID: 12163000
26. results are the first evidence of IGF-independent IGFBP-4 actions on granulosa cell steroidogenesis PMID: 12193384
27. role in sequestration of insulin-like growth factor-1 and consequent impairment of insulin-like growth factor-1 action in skeletal tissue PMID: 12733722
28. A novel SP3 binding site was identified in the promoter of IGFBP4. PMID: 14767471
29. IGFBP-4 proteolysis and local regulation of IGF availability may be altered in malignant ovarian epithelial cells PMID: 15146551
30. Data suggested that growth factor- and cytokine-mediated changes in IGFBP abundance regulate postnatal fibroblast cell. proliferation PMID: 15204833
31. IGFBP-4 is a novel dB-cAMP-induced anti-angiogenic and anti-tumorigenic mediator that may be a promising candidate for glioblastoma therapy. PMID: 16586492
32. Overexpression of IGFBP-4 in vivo has been reported to decrease the growth of prostate cancer and altered expression of IGFBP-4 in vivo in colon and other cancers needs to be explored as locally available IGFs appear to stimulate mitogenesis. (review) PMID: 16685432
33. local increased collagen synthesis was preceded by an elevation of local concentration of IGFBP-4, suggesting that IGFBP-4 may have a key role in the IGF-axis effect on the human collagen synthesis in vivo PMID: 16973813
34. the IGF system may have a limited role in the pathogenesis of GCT with PAPP-A subserving a function other than IGFBP-4 proteolysis PMID: 17177834
35. Ratios between IGFBPs and IGF (insulin-like growth factors), different IGFBPs, sequential proteolytic cleavage of IGFBPs, and association of activating proteinases are key elements in the regulation of IGF receptor stimulation. PMID: 17312271
36. IGFBP-4 may have a role in increasing necrosis and apoptosis, but in decreasing mitosis PMID: 17824980
37. conclusion: decreased IGFBP-4 tumor expression might be a step in the progression from primary to metastatic melanoma; data lend support to a recently-described novel tumor suppressor role of secreting IGFBPs in melanoma PMID: 19025658
38. IGFBP4, which can inhibit IGF action, also increased during in-vitro decidualization of cultured human ESCs. PMID: 19038974
顯示更多

收起更多
亞細胞定位：

Secreted.
數(shù)據(jù)庫鏈接：

HGNC: 5473

OMIM: 146733

KEGG: hsa:3487

STRING: 9606.ENSP00000269593

UniGene: Hs.462998

Most popular with customers

YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human